Primary Biliary Cirrhosis - Pipeline Review, H1 2017
ReportsWeb.com has announced the addition of the “Primary Biliary Cirrhosis - Pipeline Review, H1 2017” this report provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.
(EMAILWIRE.COM, June 13, 2017 ) Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Phase 0 stages are 1, 1, 9, 5 and 1 respectively.
Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/primary-biliary-cirrhosis-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001689398/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Albireo Pharma Inc
Arena Pharmaceuticals Inc
CymaBay Therapeutics Inc
Eisai Co Ltd
Enanta Pharmaceuticals Inc
Genextra Spa
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GlaxoSmithKline Plc
MediGene AG
NGM Biopharmaceuticals Inc
Novartis AG
Retrophin Inc
Shire Plc
Virobay Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001689398/discount
List of Tables
Number of Products under Development for Primary Biliary Cirrhosis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H1 2017
Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Genextra Spa, H1 2017
Primary Biliary Cirrhosis - Pipeline by Genfit SA, H1 2017
Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H1 2017
Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H1 2017
Primary Biliary Cirrhosis - Pipeline by MediGene AG, H1 2017
Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Novartis AG, H1 2017
Primary Biliary Cirrhosis - Pipeline by Retrophin Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Shire Plc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H1 2017
Primary Biliary Cirrhosis - Dormant Projects, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001689398/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Phase 0 stages are 1, 1, 9, 5 and 1 respectively.
Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/primary-biliary-cirrhosis-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001689398/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Albireo Pharma Inc
Arena Pharmaceuticals Inc
CymaBay Therapeutics Inc
Eisai Co Ltd
Enanta Pharmaceuticals Inc
Genextra Spa
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GlaxoSmithKline Plc
MediGene AG
NGM Biopharmaceuticals Inc
Novartis AG
Retrophin Inc
Shire Plc
Virobay Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001689398/discount
List of Tables
Number of Products under Development for Primary Biliary Cirrhosis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H1 2017
Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Genextra Spa, H1 2017
Primary Biliary Cirrhosis - Pipeline by Genfit SA, H1 2017
Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H1 2017
Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H1 2017
Primary Biliary Cirrhosis - Pipeline by MediGene AG, H1 2017
Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Novartis AG, H1 2017
Primary Biliary Cirrhosis - Pipeline by Retrophin Inc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Shire Plc, H1 2017
Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H1 2017
Primary Biliary Cirrhosis - Dormant Projects, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001689398/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results